These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1045 related articles for article (PubMed ID: 24074286)
1. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
2. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis. Ma H; Yang J Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330 [TBL] [Abstract][Full Text] [Related]
3. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
4. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
6. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia]. Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D; Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985 [TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
11. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. Ma Y; Liu L; Jin J; Lou Y PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027 [TBL] [Abstract][Full Text] [Related]
12. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687 [TBL] [Abstract][Full Text] [Related]
13. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344 [TBL] [Abstract][Full Text] [Related]
14. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939 [TBL] [Abstract][Full Text] [Related]
15. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821 [TBL] [Abstract][Full Text] [Related]
16. Current standard treatment of adult acute promyelocytic leukaemia. Lo-Coco F; Cicconi L; Breccia M Br J Haematol; 2016 Mar; 172(6):841-54. PubMed ID: 26687281 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645 [TBL] [Abstract][Full Text] [Related]
18. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
20. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]